Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.39 |
| ▸ | MAP3K12 | Q12852 | 13/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | DLK1 | P80370 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL625128 | 0.90 | CCNA2 (0.46) | MAP4K1MAP3K12PIK3CASYKCCNA2 | |
| SCHEMBL625407 | 0.87 | PIK3CA (0.45) | PIK3CANAMPT | |
| SCHEMBL627432 | 0.86 | RET (0.40) | MAP4K1MAP3K12PIK3CADLK1 | |
| SCHEMBL627020 | 0.85 | RET (0.40) | MAP3K12PIK3CA | |
| SCHEMBL623829 | 0.84 | F2RL3 (0.48) | SYKNAMPT | |
| SCHEMBL625456 | 0.83 | MAP3K12 (0.41) | MAP4K1MAP3K12PIK3CASYKCCNA2 | |
| SCHEMBL625422 | 0.83 | PIK3CA (0.42) | MAP3K12PIK3CA | |
| SCHEMBL626108 | 0.83 | MAP3K12 (0.42) | MAP3K12PIK3CADLK1 | |
| SCHEMBL626123 | 0.82 | RET (0.43) | MAP3K12PIK3CA | |
| SCHEMBL624985 | 0.82 | KDM4E (0.40) | MAP4K1MAP3K12PIK3CASYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012020215-A1 | AMINO- IMIDAZOLOTHIADIAZOLES FOR USE AS PROTEIN OR LIPID KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2012-02-16 | — | — | WO | disclosed |